期刊
ACS CHEMICAL BIOLOGY
卷 9, 期 10, 页码 2180-2193出版社
AMER CHEMICAL SOC
DOI: 10.1021/cb500528c
关键词
-
资金
- Swiss National Science Foundation [PP00P2_133568, 200021_129910, 200020_146776]
- University of Zurich
- Stiftung fur Wissenschaftliche Forschung of the University of Zurich
- Swiss National Science Foundation (SNF) [200021_129910, 200020_146776] Funding Source: Swiss National Science Foundation (SNF)
In the recent years, organometallic compounds have become recognized as promising anti-cancer drug candidates. While radioactive Re-186/188 compounds are already used in clinics for cancer treatment, cold Re organometallic compounds have mostly been explored as luminescent probes for cell imaging and photosensitizers in photocatalysis. However, a growing number of studies have recently revealed the potential of Re organometallic complexes as anti-cancer agents. Several compounds have displayed cytotoxicity equaling or exceeding that of the well-established anti-cancer drug cisplatin. In this review, we present the currently known Re organometallic complexes that have shown anti-proliferative activity on cancer cell lines. A particular emphasis is placed on their cellular uptake and localization as well as their potential mechanism of action.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据